A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children with Blineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Tr

Project: Research project

Project Details

StatusFinished
Effective start/end date5/1/15 → 4/30/18

Funding

  • National Marrow Donor Program
  • MedImmune, Inc.